WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE®* (CA9-SCAN)

Louvain-la-Neuve & Munich, June 6, 2008.The Munich-based biopharma­ceutical company, WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard), has signed a licensing agreement with IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB / Brussels, Belgium) for the worldwide marketing, distribution and sales of its diagnostic product candidate REDECTANE® (CA9-SCAN). The agreement gives IBA the exclusive global rights and licenses required for manufacturing and marketing the product.

REDECTANE® is an imaging diagnostic designed to support physicians in diagnosing clear cell renal cell cancer prior to surgery. REDECTANE® is a radiolabelled antibody visualized by Positron Emission Tomography (PET) and is currently in a pivotal phase III registration trial. REDECTANE® should improve cancer diagnostics and the follow-up monitoring of patients. The peak sales potential of REDECTANE® is estimated to reach over US$100 Million in the diagnosis of clear cell renal cell cancer alone.

According to the agreement, WILEX will manufacture the cold antibody and be responsible for clinical development. IBA will be responsible for manufacturing by labeling the antibody and will be responsible for distribution, sales and marketing of REDECTANE®. WILEX will receive an upfront payment, milestone payments and certain contributions-in-kind. After the planned market approval, WILEX will get 20% on ex-factory sales until a sales volume of EUR 7 million is reached. After that WILEX will get 45% on total ex-factory sales.

WILEX retains worldwide co-promotion rights and may use these to co-promote REDECTANE® amongst urologists and oncologists. The companies agreed not to disclose any further details of the agreement. IBA and WILEX had already entered into a manufacturing agreement for the ongoing Phase III registration trial in December 2006.

"We are very pleased about this commercial partnership as IBA is the ideal partner for REDECTANE®", said Professor Olaf G. Wilhelm, Chief Executive Officer of WILEX AG. "IBA possesses both the know-how and the infrastructure necessary for developing the market for REDECTANE® rapidly and comprehensively following the product's approval. IBA already markets globally its other products to radiologists, the potential customers of REDECTANE®. We will support marketing by co-promoting the product to urologists and oncologists within our worldwide network".

Pierre Mottet, Chief Executive Officer of IBA explains: "This agreement is an important milestone in the expansion of our leading position in the field of radiopharmaceutical products. We are already the leading supplier of PET radiopharmaceuticals worldwide and this partnership agreement with WILEX confirms our strategy of offering technology, materials and services to medical imaging centers from a single source. We very much look forward to our enhanced cooperation".

About REDECTANE® (CA9-SCAN)
REDECTANE® is the diagnostic candidate CA9-SCAN, which is one of two product candidates from WILEX’s late stage multi-product portfolio which is in a pivotal registration trial. REDECTANE® is a radioactively labeled form of the antibody WX-G250 and is being developed for the pre-surgical diagnosis of clear cell renal cell cancer. The labeled antibody accumulates in the tumor tissue and can be visualized by means of Positron Emission Tomography (PET). An earlier feasibility study found that a positive result with REDECTANE® was confirmed as clear cell renal cell carcinoma in 100% of the cases (positive predictive value). REDECTANE® could determine whether the patient had clear cell renal cell carcinoma before surgery and the subsequent pathology. Therefore, REDECTANE® could significantly improve and simplify treatment planning for patients suspected of having renal cancer.

* temporary name while under development

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Back to press releases